Related Experiment Video
Updated: Jul 24, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
COURSE OF POST COVID-19 DISEASE IN HEART FAILURE PATIENTS WITH MODERATELY REDUCED LEFT VENTRICULAR EJECTION FRACTION
I Rudyk1, D Babichev1, O Medentseva1
1Government Institution "L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine.
Insights
COVID-19 significantly worsens heart failure with mid-range ejection fraction (HFmrEF). Patients with a history of COVID-19 showed elevated NT-proBNP, uric acid, and poorer quality of life, indicating lasting cardiac impact.
Area of Science:
- Cardiology
- Infectious Diseases
- Biomarkers
Background:
- Heart failure with mid-range ejection fraction (HFmrEF) is a significant cardiovascular condition.
- The long-term effects of COVID-19 on cardiovascular health, particularly in HFmrEF patients, require further investigation.
Purpose of the Study:
- To assess the impact of COVID-19 on the course of HFmrEF.
- To identify specific biomarkers and clinical indicators affected by concurrent COVID-19 infection in HFmrEF patients.
Main Methods:
- A comparative study involving 72 HFmrEF patients and 18 healthy controls.
- Biomarker analysis (furin, NT-proBNP, uric acid), quality of life questionnaires (EQ-5D-5L), and cardiac ultrasound were employed.
- HFmrEF patients were subgrouped based on COVID-19 history.
Main Results:
- Patients with a history of COVID-19 exhibited significantly higher NT-proBNP levels (1002.79±215.94 pg/ml vs. 405.37±99.06 pg/ml) and uric acid (429.08±27.01 mmol/l vs. 354.44±28.75 mmol/l).
- A lower furin to NT-proBNP ratio (0.87±0.26 vs. 1.38±1.16) and reduced quality of life scores (64.21±3.04 vs. 72.81±1.82) were observed in the COVID-19 positive group.
- Increased left ventricular mass index (LVMMi) and atrial dimensions (LA, RA) were noted in HFmrEF patients with prior COVID-19.
Conclusions:
- Coronavirus infection exacerbates HFmrEF, leading to intracardiac hemodynamic disorders and persistent negative structural heart changes.
- The furin to NT-proBNP ratio may serve as a predictor for the impact of HF syndrome on patients' quality of life.
- COVID-19 poses a significant threat to the cardiovascular health of HFmrEF patients, necessitating targeted monitoring and management strategies.
Abstract:
In this study, we assessed the impact of COVID-19 on the course of HFmrEF by determining the biomarkers furin and NT-proBNP, questionnaires (EQ-5D-5L), and cardiac ultrasound. A comprehensive examination of 72 patients with HFmrEF (main group) and 18 apparently healthy individuals (control group). The main group was divided into two subgroups depending on the history of coronavirus disease. All patients gave their consent to participate in the study. In the group of patients with a history of coronavirus infection compared to the patients without a COVID-19 history were established: significantly higher concentrations of NT-proBNP (1002.79±215.94 pg/ml and 405.37±99.06 pg/ml, respectively, p-value 0.01), uric acid (429.08±27.01 mmol/l vs. 354.44±28.75 mmol/l, p-value 0.04) and a lower furin to NT-proBNP ratio (0.87± 0.26 and 1.38 ± 1.16, p-value 0.045) in blood serum; using the EQ-5D-5L questionnaire, a significant deterioration of quality of life indicators (64.21±3.04 points vs. 72.81±1.82 points by VAS, p-value 0.02); higher indicators of LVMMi (157.39±6.14 g/m2 and 138.68±6.02 g/m2, p-value 0.03), LA dimensions (43.74±0.95 mm and 41.12±0.85 mm, p-value 0.04) and RA dimensions (40.76±1.23 mm and 37.75±0.85 mm, p-value 0.04). Coronavirus infection in patients with HFmrEF leads to disorders of intracardiac hemodynamics and persistent negative structural changes of the heart. The ratio of furin to NT-proBNP serum levels can be used to determine the impact of the HF syndrome itself on the patients' subjective assessment of their quality of life.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy